{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:02:30Z","timestamp":1762459350553,"version":"3.37.3"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:00:00Z","timestamp":1445212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:00:00Z","timestamp":1445212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","award":["U01 AG031294","EY016094"],"award-info":[{"award-number":["U01 AG031294","EY016094"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12868-015-0208-9","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T12:26:54Z","timestamp":1445257614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia"],"prefix":"10.1186","volume":"16","author":[{"given":"Jia","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawren","family":"VandeVrede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujeewa","family":"Piyankarage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Tavassoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rezene T.","family":"Asghodom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel Ben","family":"Aissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"F\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavio","family":"Arancio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Pepperberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R. J.","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,19]]},"reference":[{"issue":"2","key":"208_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","volume":"9","author":"W Thies","year":"2013","unstructured":"Thies W, Bleiler L. 2013 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2013;9(2):208\u201345.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"208_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1006\/nbdi.1996.0016","volume":"3","author":"RE Tanzi","year":"1996","unstructured":"Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, Wasco W. The gene defects responsible for familial Alzheimer\u2019s disease. Neurobiol Dis. 1996;3(3):159\u201368.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"208_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. Am J Pathol. 1999;155(3):853\u201362.","journal-title":"Am J Pathol"},{"issue":"6","key":"208_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 1999;46(6):860\u20136.","journal-title":"Ann Neurol"},{"issue":"2","key":"208_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/exnr.1999.7085","volume":"158","author":"J Wang","year":"1999","unstructured":"Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer\u2019s disease from normal and pathologic aging. Exp Neurol. 1999;158(2):328\u201337.","journal-title":"Exp Neurol"},{"issue":"10","key":"208_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12(10):383\u20138.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"208_CR7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","volume":"17","author":"BP Imbimbo","year":"2009","unstructured":"Imbimbo BP. Why did tarenflurbil fail in Alzheimer\u2019s disease? J Alzheimers Dis. 2009;17(4):757\u201360.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"208_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.amjopharm.2009.06.003","volume":"7","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh MN. Drug development for Alzheimer\u2019s disease: where are we now and where are we headed? Am J Geriatr Pharmacother. 2009;7(3):167\u201385.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"10","key":"208_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrd3288","volume":"9","author":"A Extance","year":"2010","unstructured":"Extance A. Alzheimer\u2019s failure raises questions about disease-modifying strategies. Nat Rev Drug Discov. 2010;9(10):749\u201351.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"208_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1056\/NEJMe1313943","volume":"370","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J. Antiamyloid therapy for Alzheimer\u2019s disease\u2014are we on the right road? N Engl J Med. 2014;370(4):377\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"208_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/jcpt.12112","volume":"39","author":"JA Mikulca","year":"2014","unstructured":"Mikulca JA, Nguyen V, Gajdosik DA, Teklu SG, Giunta EA, Lessa EA, Tran CH, Terak EC, Raffa RB. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther. 2014;39(1):25\u201337.","journal-title":"J Clin Pharm Ther"},{"issue":"Pt 10","key":"208_CR12","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/brain\/aws234","volume":"135","author":"JA Schneider","year":"2012","unstructured":"Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135(Pt 10):3005\u201314.","journal-title":"Brain"},{"issue":"8","key":"208_CR13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.2174\/15672050113109990157","volume":"10","author":"S Negash","year":"2013","unstructured":"Negash S, Wilson RS, Leurgans SE, Wolk DA, Schneider JA, Buchman AS, Bennett DA, Arnold SE. Resilient brain aging: characterization of discordance between Alzheimer\u2019s disease pathology and cognition. Curr Alzheimer Res. 2013;10(8):844\u201351.","journal-title":"Curr Alzheimer Res"},{"issue":"5594","key":"208_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002;298(5594):789\u201391.","journal-title":"Science"},{"issue":"3","key":"208_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Inflammation and Alzheimer\u2019s disease. Neurobiol Aging. 2000;21(3):383\u2013421.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"208_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4161\/cam.3.1.7402","volume":"3","author":"A Gella","year":"2009","unstructured":"Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adhes Migr. 2009;3(1):88\u201393.","journal-title":"Cell Adhes Migr"},{"issue":"9","key":"208_CR17","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1523\/JNEUROSCI.21-09-03017.2001","volume":"21","author":"K Hirai","year":"2001","unstructured":"Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, et al. Mitochondrial abnormalities in Alzheimer\u2019s disease. J Neurosci. 2001;21(9):3017\u201323.","journal-title":"J Neurosci"},{"issue":"1","key":"208_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/157016111201140327164641","volume":"12","author":"K Stellos","year":"2014","unstructured":"Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C. Association of platelet activation with vascular cognitive impairment: implications in dementia development? Curr Vasc Pharmacol. 2014;12(1):152\u20134.","journal-title":"Curr Vasc Pharmacol"},{"issue":"14","key":"208_CR19","first-page":"394","volume":"11","author":"KJ Bangen","year":"2014","unstructured":"Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, Salmon DP, Bondi MW. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer\u2019s disease. Alzheimers Dement. 2014;11(14):394\u2013403.","journal-title":"Alzheimers Dement."},{"issue":"1\u20132","key":"208_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0169-328X(97)00125-3","volume":"49","author":"B Connor","year":"1997","unstructured":"Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer\u2019s disease. Brain Res Mol Brain Res. 1997;49(1\u20132):71\u201381.","journal-title":"Brain Res Mol Brain Res"},{"key":"208_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-3-7091-6139-5_22","volume":"62","author":"M Fahnestock","year":"2002","unstructured":"Fahnestock M, Garzon D, Holsinger RM, Michalski B. Neurotrophic factors and Alzheimer\u2019s disease: are we focusing on the wrong molecule? J Neural Transm Suppl. 2002;62:241\u201352.","journal-title":"J Neural Transm Suppl"},{"issue":"17","key":"208_CR22","doi-asserted-by":"publisher","first-page":"12463","DOI":"10.1074\/jbc.R109.080895","volume":"285","author":"A Demuro","year":"2010","unstructured":"Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem. 2010;285(17):12463\u20138.","journal-title":"J Biol Chem"},{"issue":"4","key":"208_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jalz.2013.01.017","volume":"9","author":"K Herrup","year":"2013","unstructured":"Herrup K, Carrillo MC, Schenk D, Cacace A, Desanti S, Fremeau R, Bhat R, Glicksman M, May P, Swerdlow R, et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer\u2019s disease. Alzheimers Dement. 2013;9(4):452\u2013458.e451.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"208_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd3869","volume":"11","author":"A Corbett","year":"2012","unstructured":"Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, Hagan JJ, Holmes C, Jones E, Katona C, et al. Drug repositioning for Alzheimer\u2019s disease. Nat Rev Drug Discov. 2012;11(11):833\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"208_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0361-9230(99)00275-0","volume":"52","author":"JW Marshall","year":"2000","unstructured":"Marshall JW, Cross AJ, Jackson DM, Green AR, Baker HF, Ridley RM. Clomethiazole protects against hemineglect in a primate model of stroke. Brain Res Bull. 2000;52(1):21\u20139.","journal-title":"Brain Res Bull"},{"issue":"1","key":"208_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1213\/01.ANE.0000063821.60233.7D","volume":"97","author":"D Harmon","year":"2003","unstructured":"Harmon D, Coleman E, Marshall C, Lan W, Shorten G. The effect of clomethiazole on plasma concentrations of interleukin-6, -8, -1beta, tumor necrosis factor-alpha, and neutrophil adhesion molecule expression during experimental extracorporeal circulation. Anesth Analg. 2003;97(1):13\u20138.","journal-title":"Anesth Analg"},{"issue":"8","key":"208_CR27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1096\/fj.04-3367fje","volume":"19","author":"AN Clarkson","year":"2005","unstructured":"Clarkson AN, Liu H, Rahman R, Jackson DM, Appleton I, Kerr DS. Clomethiazole: mechanisms underlying lasting neuroprotection following hypoxia-ischemia. Faseb J. 2005;19(8):1036\u20138.","journal-title":"Faseb J"},{"issue":"2","key":"208_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.neuroscience.2006.09.040","volume":"144","author":"AN Clarkson","year":"2007","unstructured":"Clarkson AN, Clarkson J, Jackson DM, Sammut IA. Mitochondrial involvement in transhemispheric diaschisis following hypoxia-ischemia: Clomethiazole-mediated amelioration. Neuroscience. 2007;144(2):547\u201361.","journal-title":"Neuroscience"},{"issue":"4","key":"208_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1527-3458.2004.tb00028.x","volume":"10","author":"MJ Wilby","year":"2004","unstructured":"Wilby MJ, Hutchinson PJ. The pharmacology of chlormethiazole: a potential neuroprotective agent? CNS Drug Rev. 2004;10(4):281\u201394.","journal-title":"CNS Drug Rev"},{"issue":"1","key":"208_CR30","first-page":"128","volume":"33","author":"GJ Hankey","year":"2002","unstructured":"Hankey GJ. Clomethiazole: an unsuccessful bachelor, but perhaps a prosperous married man? Stroke. 2002;33(1):128\u20139.","journal-title":"Stroke"},{"issue":"2","key":"208_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bph.12454","volume":"171","author":"L Vandevrede","year":"2014","unstructured":"Vandevrede L, Tavassoli E, Luo J, Qin Z, Yue L, Pepperberg DR, Thatcher GR. Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABAA receptor potentiation. Br J Pharmacol. 2014;171(2):389\u2013402.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"208_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1042\/BJ20120653","volume":"446","author":"AF Teich","year":"2012","unstructured":"Teich AF, Arancio O. Is the amyloid hypothesis of Alzheimer\u2019s disease therapeutically relevant? Biochem J. 2012;446(2):165\u201377.","journal-title":"Biochem J"},{"key":"208_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.neuro.21.1.127","volume":"21","author":"AJ Silva","year":"1998","unstructured":"Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu Rev Neurosci. 1998;21:127\u201348.","journal-title":"Annu Rev Neurosci"},{"issue":"23","key":"208_CR34","doi-asserted-by":"crossref","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","volume":"19","author":"YF Lu","year":"1999","unstructured":"Lu YF, Kandel ER, Hawkins RD. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci. 1999;19(23):10250\u201361.","journal-title":"J Neurosci"},{"issue":"3","key":"208_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.neuron.2005.01.011","volume":"45","author":"HG Wang","year":"2005","unstructured":"Wang HG, Lu FM, Jin I, Udo H, Kandel ER, de Vente J, Walter U, Lohmann SM, Hawkins RD, Antonova I. Presynaptic and postsynaptic roles of NO, cGK, and RhoA in long-lasting potentiation and aggregation of synaptic proteins. Neuron. 2005;45(3):389\u2013403.","journal-title":"Neuron"},{"key":"208_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1326-6-60","volume":"6","author":"S Pugazhenthi","year":"2011","unstructured":"Pugazhenthi S, Wang M, Pham S, Sze CI, Eckman CB. Downregulation of CREB expression in Alzheimer\u2019s brain and in Abeta-treated rat hippocampal neurons. Mol Neurodegener. 2011;6:60.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"208_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1155\/2009\/618619","volume":"27","author":"J Satoh","year":"2009","unstructured":"Satoh J, Tabunoki H, Arima K. Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus. Dis Markers. 2009;27(5):239\u201352.","journal-title":"Dis Markers"},{"key":"208_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-0447.1986.tb10530.x","volume":"329","author":"SO Ogren","year":"1986","unstructured":"Ogren SO. Chlormethiazole\u2013mode of action. Acta Psychiatr Scand Suppl. 1986;329:13\u201327.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"3","key":"208_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0014-2999(02)02233-1","volume":"452","author":"RM Nelson","year":"2002","unstructured":"Nelson RM, Green AR, Hainsworth AH. Electrophysiological actions of g-aminobutyric acid and clomethiazole on recombinant GABAA receptors. Eur J Pharmacol. 2002;452(3):255\u201362.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"208_CR40","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/cercor\/bht048","volume":"24","author":"A Neitz","year":"2014","unstructured":"Neitz A, Mergia E, Imbrosci B, Petrasch-Parwez E, Eysel UT, Koesling D, Mittmann T. Postsynaptic NO\/cGMP increases NMDA receptor currents via hyperpolarization-activated cyclic nucleotide-gated channels in the hippocampus. Cereb Cortex. 2014;24(7):1923\u201336.","journal-title":"Cereb Cortex"},{"key":"208_CR41","volume-title":"Methods of behavior analysis in neuroscience","author":"J Buccafusco","year":"2009","unstructured":"Buccafusco J. The Revival of scopolamine reversal for the assessment of cognition-enhancing drugs. In: Buccafusco J, editor. Methods of behavior analysis in neuroscience. 2nd ed. Boca Raton: CRC Press; 2009.","edition":"2"},{"issue":"1\u20132","key":"208_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0006-8993(91)91382-B","volume":"568","author":"C Tomaz","year":"1991","unstructured":"Tomaz C, Dickinson-Anson H, McGaugh JL. Amygdala lesions block the amnestic effects of diazepam. Brain Res. 1991;568(1\u20132):85\u201391.","journal-title":"Brain Res"},{"key":"208_CR43","first-page":"261","volume":"11","author":"R Charonnat","year":"1956","unstructured":"Charonnat R, Lechat P, Chareton J. From a convulsive to an anticonvulsive product in the thiamine series. Therapie. 1956;11:261\u20134.","journal-title":"Therapie"},{"issue":"44","key":"208_CR44","doi-asserted-by":"publisher","first-page":"30538","DOI":"10.1074\/jbc.M114.600833","volume":"289","author":"LM Tai","year":"2014","unstructured":"Tai LM, Koster KP, Luo J, Lee SH, Wang YT, Collins NC, Ben Aissa M, Thatcher GR, LaDu MJ. Amyloid-beta Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in vivo. J Biol Chem. 2014;289(44):30538\u201355.","journal-title":"J Biol Chem."},{"issue":"5580","key":"208_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science"},{"issue":"4","key":"208_CR46","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ. The molecular pathology of Alzheimer\u2019s disease. Neuron. 1991;6(4):487\u201398.","journal-title":"Neuron"},{"issue":"9","key":"208_CR47","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","volume":"60","author":"P Giannakopoulos","year":"2003","unstructured":"Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease. Neurology. 2003;60(9):1495\u2013500.","journal-title":"Neurology"},{"issue":"2","key":"208_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76(2):185\u2013205.","journal-title":"Ann Neurol"},{"issue":"2","key":"208_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/alzrt244","volume":"6","author":"JH Toyn","year":"2014","unstructured":"Toyn JH, Ahlijanian MK. Interpreting Alzheimer\u2019s disease clinical trials in light of the effects on amyloid-beta. Alzheimers Res Ther. 2014;6(2):14.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"208_CR50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2125.2010.03830.x","volume":"71","author":"K Akter","year":"2011","unstructured":"Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer\u2019s disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71(3):365\u201376.","journal-title":"Br J Clin Pharmacol"},{"issue":"17","key":"208_CR51","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/WNL.0b013e318217e7a4","volume":"76","author":"J Li","year":"2011","unstructured":"Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, Yan JC, Zhou HD. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76(17):1485\u201391.","journal-title":"Neurology"},{"issue":"5800","key":"208_CR52","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1126\/science.1132813","volume":"314","author":"ED Roberson","year":"2006","unstructured":"Roberson ED, Mucke L. 100\u00a0years and counting: prospects for defeating Alzheimer\u2019s disease. Science. 2006;314(5800):781\u20134.","journal-title":"Science"},{"issue":"1","key":"208_CR53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/01.STR.31.1.82","volume":"31","author":"NG Wahlgren","year":"2000","unstructured":"Wahlgren NG, Diez-Tejedor E, Teitelbaum J, Arboix A, Leys D, Ashwood T, Grossman E. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. Stroke. 2000;31(1):82\u20135.","journal-title":"Stroke"},{"issue":"1","key":"208_CR54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1161\/hs0102.101478","volume":"33","author":"P Lyden","year":"2002","unstructured":"Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, et al. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke. 2002;33(1):122\u20138.","journal-title":"Stroke"},{"issue":"6","key":"208_CR55","first-page":"647","volume":"8","author":"UH Lindberg","year":"1971","unstructured":"Lindberg UH. Hypnotic and anticonvulsant agents related to the thiazole part of thiamine. Acta Pharm Suec. 1971;8(6):647\u201360.","journal-title":"Acta Pharm Suec"},{"issue":"2","key":"208_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0028-3908(01)00052-1","volume":"41","author":"RM Nelson","year":"2001","unstructured":"Nelson RM, Hainsworth AH, Lambert DG, Jones JA, Murray TK, Richards DA, Gabrielsson J, Cross AJ, Green AR. Neuroprotective efficacy of AR-A008055, a clomethiazole analogue, in a global model of acute ischaemic stroke and its effect on ischaemia-induced glutamate and GABA efflux in vitro. Neuropharmacology. 2001;41(2):159\u201366.","journal-title":"Neuropharmacology"},{"issue":"1","key":"208_CR57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s002130100762","volume":"157","author":"MI Colado","year":"2001","unstructured":"Colado MI, O\u2019Shea E, Esteban B, Green AR. Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA (\u201cecstasy\u201d)-induced neurodegeneration in rat brain. Psychopharmacology. 2001;157(1):82\u20138.","journal-title":"Psychopharmacology"},{"issue":"3","key":"208_CR58","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1096\/fj.03-0739com","volume":"18","author":"PR Louzada","year":"2004","unstructured":"Louzada PR, Paula Lima AC, Mendonca-Silva DL, Noel F, De Mello FG, Ferreira ST. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer\u2019s disease and other neurological disorders. FASEB J. 2004;18(3):511\u20138.","journal-title":"FASEB J"},{"issue":"4","key":"208_CR59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.neures.2005.04.008","volume":"52","author":"BY Lee","year":"2005","unstructured":"Lee BY, Ban JY, Seong YH. Chronic stimulation of GABAA receptor with muscimol reduces amyloid beta protein (25\u201335)-induced neurotoxicity in cultured rat cortical cells. Neurosci Res. 2005;52(4):347\u201356.","journal-title":"Neurosci Res"},{"issue":"1","key":"208_CR60","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","volume":"106","author":"M Marcade","year":"2008","unstructured":"Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, Schweighoffer F, Desire L. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008;106(1):392\u2013404.","journal-title":"J Neurochem"},{"issue":"4","key":"208_CR61","first-page":"613","volume":"117","author":"RA Rissman","year":"2011","unstructured":"Rissman RA, Mobley WC. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer\u2019s disease. J Neurochem. 2011;117(4):613\u201322.","journal-title":"J Neurochem"},{"issue":"4","key":"208_CR62","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2174\/156720507781788873","volume":"4","author":"D Tweedie","year":"2007","unstructured":"Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res. 2007;4(4):378\u201385.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"208_CR63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2009.01.006","volume":"34","author":"FE McAlpine","year":"2009","unstructured":"McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer\u2019s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009;34(1):163\u201377.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"208_CR64","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease. Neurology. 2001;56(1):127\u20139.","journal-title":"Neurology"},{"issue":"4","key":"208_CR65","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380.","journal-title":"Ann Neurol"},{"issue":"11","key":"208_CR66","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1172\/JCI22831","volume":"114","author":"B Gong","year":"2004","unstructured":"Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest. 2004;114(11):1624\u201334.","journal-title":"J Clin Invest"},{"issue":"5","key":"208_CR67","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0896-6273(91)90273-3","volume":"7","author":"HS Phillips","year":"1991","unstructured":"Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer\u2019s disease. Neuron. 1991;7(5):695\u2013702.","journal-title":"Neuron"},{"issue":"3","key":"208_CR68","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1152\/jn.2002.88.3.1270","volume":"88","author":"YF Lu","year":"2002","unstructured":"Lu YF, Hawkins RD. Ryanodine receptors contribute to cGMP-induced late-phase LTP and CREB phosphorylation in the hippocampus. J Neurophysiol. 2002;88(3):1270\u20138.","journal-title":"J Neurophysiol"},{"issue":"6535","key":"208_CR69","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/376074a0","volume":"376","author":"O Arancio","year":"1995","unstructured":"Arancio O, Kandel ER, Hawkins RD. Activity-dependent long-term enhancement of transmitter release by presynaptic 3\u2032,5\u2032-cyclic GMP in cultured hippocampal neurons. Nature. 1995;376(6535):74\u201380.","journal-title":"Nature"},{"issue":"1","key":"208_CR70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nn.3592","volume":"17","author":"J Kim","year":"2014","unstructured":"Kim J, Kwon JT, Kim HS, Josselyn SA, Han JH. Memory recall and modifications by activating neurons with elevated CREB. Nat Neurosci. 2014;17(1):65\u201372.","journal-title":"Nat Neurosci"},{"issue":"5","key":"208_CR71","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0092-8674(02)00657-8","volume":"108","author":"A Barco","year":"2002","unstructured":"Barco A, Alarcon JM, Kandel ER. Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell. 2002;108(5):689\u2013703.","journal-title":"Cell"},{"issue":"3","key":"208_CR72","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.npp.1301054","volume":"32","author":"BM Bennett","year":"2007","unstructured":"Bennett BM, Reynolds JN, Prusky GT, Douglas RM, Sutherland RJ, Thatcher GRJ. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester. Neuropsychopharmacology. 2007;32(3):505\u201313.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"208_CR73","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1515\/REVNEURO.2006.17.5.497","volume":"17","author":"D Puzzo","year":"2006","unstructured":"Puzzo D, Palmeri A, Arancio O. Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer\u2019s disease. Rev Neurosci. 2006;17(5):497\u2013523.","journal-title":"Rev Neurosci"},{"key":"208_CR74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.brainres.2011.02.057","volume":"1386","author":"M Javadi-Paydar","year":"2011","unstructured":"Javadi-Paydar M, Rayatnia F, Fakhraei N, Zakeri M, Mirazi N, Norouzi A, Dehpour AR. Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: involvement of nitric oxide. Brain Res. 2011;1386:89\u201399.","journal-title":"Brain Res"},{"issue":"6","key":"208_CR75","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1111\/j.1460-9568.2005.03993.x","volume":"21","author":"WL Chien","year":"2005","unstructured":"Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, Fu WM. Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1. Eur J Neurosci. 2005;21(6):1679\u201388.","journal-title":"Eur J Neurosci"},{"issue":"3","key":"208_CR76","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/jpet.102.041616","volume":"306","author":"AV Terry Jr","year":"2003","unstructured":"Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306(3):821\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4558","key":"208_CR77","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"RT Bartus","year":"1982","unstructured":"Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408\u201314.","journal-title":"Science"},{"issue":"6","key":"208_CR78","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ana.20101","volume":"55","author":"F Trinchese","year":"2004","unstructured":"Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP\/PS1 mice. Ann Neurol. 2004;55(6):801\u201314.","journal-title":"Ann Neurol"},{"issue":"20","key":"208_CR79","doi-asserted-by":"publisher","first-page":"13217","DOI":"10.1073\/pnas.172504199","volume":"99","author":"OV Vitolo","year":"2002","unstructured":"Vitolo OV, Sant\u2019Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid beta -peptide inhibition of the PKA\/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA. 2002;99(20):13217\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"208_CR80","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1530-0277.2006.00005.x","volume":"30","author":"YM Cha","year":"2006","unstructured":"Cha YM, Li Q, Wilson WA, Swartzwelder HS. Sedative and GABAergic effects of ethanol on male and female rats. Alcohol Clin Exp Res. 2006;30(1):113\u20138.","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"208_CR81","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2174\/156720506779025233","volume":"3","author":"CH Kawas","year":"2006","unstructured":"Kawas CH, Corrada MM. Alzheimer\u2019s and dementia in the oldest-old: a century of challenges. Curr Alzheimer Res. 2006;3(5):411\u20139.","journal-title":"Curr Alzheimer Res"},{"issue":"8","key":"208_CR82","doi-asserted-by":"publisher","first-page":"e70740","DOI":"10.1371\/journal.pone.0070740","volume":"8","author":"L VandeVrede","year":"2013","unstructured":"VandeVrede L, Abdelhamid R, Qin Z, Choi J, Piyankarage S, Luo J, Larson J, Bennett BM, Thatcher GR. An NO donor approach to neuroprotective and procognitive estrogen therapy overcomes loss of NO synthase function and potentially thrombotic risk. PLoS One. 2013;8(8):e70740.","journal-title":"PLoS One"},{"issue":"7","key":"208_CR83","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1021\/jm201504s","volume":"55","author":"IT Schiefer","year":"2012","unstructured":"Schiefer IT, Vandevrede L, Fa M, Arancio O, Thatcher GR. Furoxans (1,2,5-Oxadiazole-N-Oxides) as novel NO mimetic neuroprotective and procognitive agents. J Med Chem. 2012;55(7):3076\u201387.","journal-title":"J Med Chem"},{"issue":"15","key":"208_CR84","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1021\/jm300353r","volume":"55","author":"Z Qin","year":"2012","unstructured":"Qin Z, Luo J, VandeVrede L, Tavassoli E, Fa M, Teich AF, Arancio O, Thatcher GR. Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. J Med Chem. 2012;55(15):6784\u2013801.","journal-title":"J Med Chem"},{"issue":"9","key":"208_CR85","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/ml2000033","volume":"2","author":"S Abdul-Hay","year":"2011","unstructured":"Abdul-Hay S, Schiefer IT, Chandrasena RE, Li M, Abdelhamid R, Wang YT, Tavassoli E, Michalsen B, Asghodom RT, Luo J, et al. NO-SSRIs: nitric oxide chimera drugs incorporating a selective serotonin reuptake inhibitor. ACS Med Chem Lett. 2011;2(9):656\u201361.","journal-title":"ACS Med Chem Lett"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-015-0208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12868-015-0208-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-015-0208-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-015-0208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T15:42:14Z","timestamp":1589470934000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/s12868-015-0208-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,19]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1186\/s12868-015-0208-9","relation":{},"ISSN":["1471-2202"],"issn-type":[{"type":"electronic","value":"1471-2202"}],"subject":[],"published":{"date-parts":[[2015,10,19]]},"assertion":[{"value":"25 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"67"}}